Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Excellent, let's hope it's a good update and not a delay in delivery from OpSis.
WTF, wouldn't that just be our luck. Has anyone confirmed with Management on whether they were affected by that?
I do not think that we will get a shareholder update until August. Here's my logic:
At a minimum they give us 1 PR per month. We already received our June PR (Annual shareholder meeting date) so to not see another PR this month wouldn't be unusual.
Also, they should receive the prototype devices back from OPSIS in "early summer" which I take to mean July so there is our minimum 1 PR for July. AKA "we received the devices back and now we have to coat and test them...we are excited...need another month or so to test...yada yada yada"
In August we have the ASM on 8/21. The ASM is usually when they provide a more comprehensive update to investors so this is when I think we will finally get one. In addition, by then they will have had time to coat the devices from OPSIS with their new material and conduct some testing which they may or may not report to us based on how well the devices performed.
On top of all that, they are currently trying to fill a private placement right now so they are likely enticing investors with information that would have comprised a Shareholder update. As a result, they have no need to update the rest of us and it is probably in their best interest not to so that investors in the PP feel like they have the inside scoop.
A little pessimistic, I know....Still looking forward to August and the update at that time though...
Once the RS takes effect and the company then raises cash through another private placement it should be a great buy opportunity.
They need a lot more money in order to speed up their clinical development and continue with additional clinical trials.One of my main concerns while researching this company is the lack of cash on hand.
I think we will be lucky if the Frauhofer work is completed before the end of the year.
Thanks for the reply, both of you. I'm very upbeat on the developments here and am looking forward to an exciting (hopefully in the best way possible) 3rd and 4th quarter this year.
On another note, is there a maximum time that the K trial will run or is that entirely based upon SAEs experienced? In other words, could the trial potentially go on for quite a bit longer if SAEs don't develop soon or is there a max time frame like 30 months, 36 months etc?
Thanks for the reply Daubers, I also agree that there are many exciting things going on with CTIX. IMO (rather, it is my hope) there will be much to celebrate in the late 3rd quarter, early 4th quarter. However, you posted on the wrong message board - this is for another company
Reverse Split was approved by shareholders during the shareholder meeting at the end of May this year. Will be interesting to see what management settles on and when they will implement.
I'm concerned that they are trying to uplist too soon. If they uplist this early in the game they will likely be manipulated and shorted which is rampant in big board stocks that are development stage.
If you are a long ways to product approval and have no other source of revenue except for private placements then this is a longgg ride up and down, up and down....UP briefly when it's time to raise money (or great early trial results are had), and DOWN when wall street wants to make money by shorting which is more predictable and easier for them to do....until the company has a drug approved and then it's up for a good while.
Correct me if I'm wrong but I believe the B trial for ABSSI is on par to complete enrollment in August. Results won't be for a couple months after that as they will then have to finish treating the last patients, receive and analyze results, etc.
Is there an 8-k for the agreement? Would like to know the length of time that the agreement is in place for. Usually there is a time frame or estimate..
"I was a skeptic; it's almost too good to be true,'' says co-lead author Dr. John S. Kuo, associate professor of neurosurgery and director of the comprehensive brain tumor program at the UW School of Medicine and Public Health.
"It is a very broad cancer-targeting agent in terms of the many different cancers that tested positive. The APC analogs even sometimes revealed other sites of cancer in patients that were small, asymptomatic and previously undetected by physicians."
http://medicalxpress.com/news/2014-06-tumor-targeting-agent-images-wide-variety.html
Just stumbled onto this company from an article on phys.org.
This company reminds of CYTR quite a bit. If this company is/has been able to attach a chemotherapy agent to their compound to selectively "seek and destroy" cancer cells (including cancer stem cells) throughout the body and including in the brain then this will be quite an achievement in the field of cancer and very similar (but seemingly more effective) when compared to CYTR. I would not be surprised to see this developed under a fast track designation of sorts.
If management is not currently looking at developing this platform under a fast track designation then they are doing themselves, cancer patients, and their investors a disservice.
I plan to do some more DD on this company and their platform. Quite an attractive share price although still very early in development.
Given that CTIX presented some of the Kevetrin patient testing results during the R & R conference in September 2013, perhaps they will present additional data at this year's R&R investor conference? This year it will take place from September 8-10th and although they aren't currently on the list of presenters/attendees, I'd imagine that there is still more time to sign up.
http://www.meetmax.com/sched/event_23003/~public/conference_companies.html?event_id=23003
Nothing you say ever comes true. But, in this case it has been a while since the last PR so odds are in your favor that we should see something. I doubt it will be revenues though.
Dalavance has to be injected, it is administered intravenously so the patient has to go to the doctors office once a week for two weeks to get an injection/infusion. To me, this is a pretty big negative both on having to go back to the doctor's office a week later AND to have to get an injection.
How is Brilacidin administered? If given orally via pill form, all else relatively equal this would be looked at as a huge advantage IMO.
Not sure but that's the impression I got from earlier posts yesterday and today...
Might be wrong but I could have sworn that somebody used the words "over-subscribed" in relation to the PP.
How much money did they raise through the PP?
Given the August 21st date for the shareholder meeting, I'm assuming they plan to have at least a few specs from the prototype testing that they intend to disclose on or by that date...
First I've heard of a private placement...Does Lauro get a cut of that as well?
Mid-year could include July as well. Depends on how you look at it.
Cautious ramp up, can't blame him - better safe than sorry. Maybe the next doubling in June will allow for production to hit the tonnage milestone.
Can anyone remind me where they are at with Big Red? I thought we heard about this recently but can't remember what was said about it, if anything. TIA!
I think there is a possibility that it's more than LPC but historically the share price always finds a way to "mysteriously" (without news) make it above $1 for the number of days needed to tap LPC before sinking back down to the sub-dollar range again. This happens every year without fail - not necessarily at the same time of year, but when needed.
Just referencing the sale of shares to LPC I think. At least, that is what I was referring to earlier.
In order to uplist I think they will probably have to do a reverse split and in this case I don't think it would be a bad thing at all. Due to the number of shares issued, they will never be able to reach the minimum share price requirements for an uplist until they do. Once uplisted, then institutions could come on board and load up so I would see that event as a positive.
IMO this spike in volume and share price is related to the usual unspoken behind-the-scenes financing activities and nothing more as history has proven this trend. After we get working prototypes with commercialization-worthy testing results I'll start to believe it's something more..
Yes I suppose if you haven't already done your DD that would be a nice PR to read.
I'm confused about the price spike, not sure people are reading the entire Press Release. This is relatively old news except for the update on patients that didn't finish PR Therapy in a trial done years ago in India. This is not results from the clinical trial with DaVita.
Thanks for the clarification AR, was not aware of the information on the OpSis website. That about matches up with my expectations - I'm sure it will take some time for Lightwave to coat and test the devices as well so I'm not really expecting any test results until September/October. Still hoping for an all encompassing update soon on what they're up to these days though.
Only one more month to go until the start of the "early summer" time frame for the OpSis un-coated prototype delivery...Enjoying the price rise today but historically these random spike have been related to financing and only temporary. Hope they give us a more comprehensive update soon.
Quite a good pickup - he must truly see some potential here at the very least. Guess this answers everyone's funding question? Assuming the prototype testing goes well this summer.
Liked that post Six, also liked this:
"He served as the Director of Technology Commercialization at IBM where he was responsible for transitioning technologies from research labs to the market. Also, he was the Director of New Business Development for Motorola."
This guy must have some highly valuable insight and contacts.
So if we can reduce a manufacturer's production costs by 23%, what does this equate to as far as revenue for Natcore? How will the deal likely be structured or do we not have any clue at this point? I assume an upfront payment and some cut of manufacturer's revenues?
Is Sanmina where Marcelli used to work?
Prototypes aren't due back from OpSis until "early summer". My understanding is that they then have to coat them with material and run each one through a battery of tests.
My guess is that they'll have concrete numbers for a data sheet in September or October. Of course, they should have an indication of how devices are functioning prior to then.
Anyone else notice the "Invest in KBLB" ads on Ihub? Kind of funny. Looks like they are trying to get their name out there now.
Please post a link to that information (lawsuit against Fresenius)
Thanks for the reply Joe. I guess when you're dealing with these large companies they move a lot slower than the smaller "startups" do.
May be a good time to start considering a position again.
Anyone know when AEMD's patents expire???
I am absolutely baffled at the length of time it is taking AEMD to get their clinical trial up and running. I used to follow this company closely years ago and they were seemingly in the same place progress-wise. Now I just pop in from time to time to see where they are at.
Any idea when this small trial will start? For whatever reason it took them several years to get their IND put together and approved by the FDA and this isn't even a drug, it is a DEVICE! Makes me question their ability to put together and submit an IND for a cancer trial by the end of this year
The technology seems so promising and straightforward, I just don't understand the perpetual barriers to progress! Seems like such a slam dunk given the data we saw overseas and also with regard to efficacy in removing exosomes.
Lol buz. I say let's sell to anyone who will pay an acceptable price...ASAP
Ok so that was inferred from an old PR - was just curious why I hadn't heard about it recently. Hopefully we'll get an update soon.
"....than the u of bologna validating the efficacy of kevetrin by asking for a formulation at 75 or below. "
Did this happen? Sorry if this has been discussed but I think I missed it if it was. Any links on this?
TIA